TAG:
cap
Mass. AG Coakley Cites Two Labs in 48-Count Medicaid Kickback Case
By Robert Michel | From the Volume XX No. 4 – March 25, 2013 Issue
MASSACHUSETTS ATTORNEY GENERAL Martha Coakley has cited two lab companies in a case involving kickbacks related to drugs of abuse testing. Coakley’s office made the announcement on March 8. Coakley alleges that fees were collected from patients illegally and that prescriptions for medications were…
Mass Spectrometry Is Finding Larger Role in Clinical Labs
By Joseph Burns | From the Volume XX No. 4 – March 25, 2013 Issue
CEO SUMMARY: Mass spectrometry is a diagnostic technology that is transforming clinical labs and improving care at a rapid pace. The current generation of instruments is capable of supporting a faster time-to-answer and provides improved accuracy and specificity over many existing methods…
Urologists Weigh in on Prostate Biopsy Testing
By Joseph Burns | From the Volume XX No. 3 – March 4, 2013 Issue
CEO SUMMARY: Based on an impressive number of 4,230,129 vials collected from 437,937 biopsies, the new study is expected to add fuel to the fire of the ongoing debate about the appropriate number of prostate biopsies physicians should collect and refer to pathology labs for cancer testing…
March 4, 2013 “Intelligence: Late-Breaking Lab News”
By Robert Michel | From the Volume XX No. 3 – March 4, 2013 Issue
Even if not billion-dollar transactions, there are some interesting deals unfolding in the in vitro diagnostics (IVD) marketplace. Last month, HYCOR Biomedical, Inc., of Garden Grove, California, sold its Kova urinalysis system and business “to an affiliate of One …
LipoScience Completes IPO, Raises $44.9 Million from Sale
By Robert Michel | From the Volume XX No. 3 – March 4, 2013 Issue
IT HAS BEEN A WHILE since a laboratory company has successfully completed an initial public offering (IPO). Thus, it is notable that LipoScience Inc., of Raleigh, North Carolina, recently accomplished that feat. On January 24, 2013, Liposcience closed its IPO and raised $44.9 millio…
Two MTs Launch New Lab In Aberdeen, North Carolina
By Robert Michel | From the Volume XX No. 3 – March 4, 2013 Issue
CEO SUMMARY: Although located in the same region as two of the nation’s largest laboratory companies, newly-created Triune Laboratory, Inc., is reporting steady growth and acceptance by physicians in the community. Founded by two medical technologists and partially funded by a pathologi…
Predicting the End of Fee-for-Service Medicine
By R. Lewis Dark | From the Volume XX No. 3 – March 4, 2013 Issue
HOW DISRUPTIVE WILL THE END OF FEE-FOR-SERVICE MEDICINE be to the lab testing industry? I ask this question because we are about to leave the era of fee-for-service (FFS) medicine and move into the era of value-based and bundled reimbursement. Since World War II, FFS has been the overwhelmingly domi…
Low 2013 Molecular Rates May Bankrupt Some Labs
By R. Lewis Dark | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Many of the recently issued reimbursement rates for molecular diagnostic tests are inadequate and in fact are lower than the cost of running the tests, lab experts say. Smaller laboratories that specialize in developing and selling molecular tests could be forced to close. As…
Manhattan Labs Gets Infusion of Equity Cash
By Joseph Burns | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Manhattan Labs tapped a private equity company for growth capital last month. The company says its strategy is to deliver concierge-level quality lab services to the high-end physicians and patients within the tri-state area of New York, New Jersey, and Connecticut. These are…
Lawyers Share Insights about ACO Contracting
By Joseph Burns | From the Volume XX No. 2 February 11, 2013 Issue
CEO SUMMARY: Most pathologists have yet to be involved in any substantial contractual negotiations that would allow them to assume a significant role in accountable care organizations (ACOs). Instead, hospitals and health systems are putting the building blocks in place by acquiring physi…
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized